Buckingham Strategic Wealth’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$750K Sell
5,257
-938
-15% -$124K 0.01% 384
2024
Q1
$795K Sell
6,195
-145
-2% -$17.3K 0.01% 375
2023
Q4
$656K Buy
6,340
+768
+14% +$75.9K 0.01% 394
2023
Q3
$507K Buy
5,572
+660
+13% +$58.1K 0.01% 415
2023
Q2
$397K Buy
4,912
+456
+10% +$37.3K 0.01% 476
2023
Q1
$302K Hold
4,456
0.01% 482
2022
Q4
$302K Buy
+4,456
New +$261K 0.01% 484

Other funds holding NVO

Buckingham Strategic Wealth's NVO Position: Q2 2024 in Review

Buckingham Strategic Wealth reduced its Novo Nordisk (NVO) stake by 15% in Q2 2024, selling an estimated $124K and leaving 5,257 shares worth $750K. The position accounts for 0.01% of the portfolio, ranked #384.

Buckingham Strategic Wealth first reported a position in NVO in Q4 2022 and has held it in 7 quarters since. The position peaked at $795K in Q1 2024. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Buckingham Strategic Wealth held 5,257 shares of Novo Nordisk worth $750K as of Q2 2024.
  • Buckingham Strategic Wealth sold 938 Novo Nordisk shares in Q2 2024, an estimated $124K.
  • Novo Nordisk made up 0.01% of Buckingham Strategic Wealth's portfolio in Q2 2024, its #384 holding.
  • Buckingham Strategic Wealth first reported a position in Novo Nordisk in Q4 2022 and has held it in 7 quarters since.
  • Buckingham Strategic Wealth's Novo Nordisk position peaked at $795K in Q1 2024.
  • 1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.